Document text
Principal Investigator: Ya-Wen Chen
Organization: UNIVERSITY OF SOUTHERN CALIFORNIA
Fiscal Year: 2021
Award: $421,219
Funding agency: National Heart Lung and Blood Institute
Project Summary
In December of 2019, a novel coronavirus, now referred to as severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), struck Wuhan, China and unleashed the current coronavirus disease (COVID-19) pandemic. There are currently no
medications or vaccines proven to be effective for the treatment or prevention of COVID-19. There is an urgent need to
identify effective therapeutic options: a vaccine and/or drugs that can effectively cure the disease. Although a vaccine will
be the ultimate way to combat the virus as a community, antivirals are likely to be developed and approved faster, especially
since a broadly available and effective vaccine is likely years away. Antivirals would hugely benefit the population that is
currently affected by the virus, helping individuals recover and reducing the number of deaths. Antivirals would also reduce
the number of positive carriers and thus curb the spread of the disease.
This proposal aims to develop an efficient antiviral to impede the virus’ entry into cells, specifically into lung alveolar type
II (AT2) cells, the stem cells of the distal lung. Thanks to recent studies, we know which “door” (a receptor called ACE2) and
“key” (a protease called TMPRSS2) the virus uses to enter cells. Our goal is to remove the “key” so the virus cannot open
the “door” and enter host cells. We will use a recently developed 3-dimensional (3D) in vitro lung organoid model that
recapitulates many aspects of lung structure and the cellular environment and that has been used to study respiratory
viruses, including SARS-CoV-2. This system represents tissues better than cell lines, but offers the benefit of being less
complex than tissue explants or animal models. In addition, we have generated a panel of highly sensitive and specific
mouse monoclonal antibodies (mAbs) directed against TMPRSS2. In preliminary studies, the lead TMPRSS2 mAb, AL20,
shows no signs of cytotoxicity with a trend towards inhibition of SARS-CoV-2 pseudovirus entry in cell lines. Furthermore,
we have identified at least two serine protease inhibitors (serpins) that form complexes with TMPRSS2, and the presence
of these complexes is inversely correlated with the SARS-CoV-2 infection rate. These findings lead to our hypothesis that
targeting TMPRSS2 can inhibit SARS-CoV-2 viral entry and spread.
To test our hypothesis, we will first test the efficacy of AL20 for blocking the entry of SARS-CoV-2 into AT2 cells in lung
organoids, and elucidate the underlying mechanisms. We will then evaluate the effects of serpins on TMPRSS2 activity and
SARS-CoV-2 viral entry and spread. Finally, to explore the feasibility of advancing AL20 to human trials, we also propose to
humanize and test AL20 in available K18-hACE2 mice. This transgenic strain expresses human ACE2, regulated by the KRT18
promoter that directs expression to lung epithelia, to provide the pre-clinical data necessary to test the feasibility of
advancing to human clinical trials.
These studies will provide critical insights into the mechanisms whereby TMPRSS2 regulates SARS-CoV-2 entry, and suggest
potential therapeutic candidates against COVID-19. The proposed work has the potential to impact the lives of millions of
individuals affected by COVID-19 and other respiratory viruses, such as influenza A, that use TMPRSS2 to enter cells.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><3-D><3-Dimensional><3D><ACE2><Affect><Alveolar><Animal Model><Animal Models and Related Studies><Antibodies><Antiviral Agents><Antiviral Drugs><Antivirals><Apoptosis><Apoptosis Pathway><Binding><Binding Proteins><Body Tissues><COVID><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 S protein><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 pandemic><COVID-19 prevention><COVID-19 public health crisis><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 therapy><COVID-19 treatment><COVID-19 virus><COVID19><COVID19 S protein><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 pandemic><COVID19 prevention><COVID19 public health crisis><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 therapy><COVID19 treatment><COVID19 virus><CV-19><CV19><Catalytic Core><Catalytic Domain><Catalytic Region><Catalytic Site><Catalytic Subunit><Cell Body><Cell Line><Cell Survival><Cell Viability><CellLine><Cells><Cessation of life><China><Clinical Data><Clinical Treatment Moab><Clinical Trials><CoV disease><CoV emergence><CoV-2><CoV2><Communities><Complex><Data><Death><Disease><Disorder><Distal><Dose><Drugs><Endocytosis><Environment><Epithelial><Epithelial Cells><Epitheliasin Gene><Esteroproteases><Goals><Human><In Vitro><Individual><Infection><Inflammation><Influenza A><Influenza A virus><Influenza Viruses Type A><Influenzavirus A><K-18><K-18 conjugate><K18><K18 combination><Lead><Ligand Binding Protein><Ligand Binding Protein Gene><Lung><Lung Respiratory System><Lung damage><Lytotoxicity><Mainland China><Medication><Mice><Mice Mammals><Modeling><Modern Man><Molecular><Molecular Interaction><Monoclonal Antibodies><Murine><Mus><Organoids><Orthomyxovirus Type A><PRSS10><Pb element><Peptidases><Peptide Hydrolases><Pharmaceutic Preparations><Pharmaceutical Preparations><Population><Process><Progenitor Cells><Programmed Cell Death><Protease Gene><Proteases><Protein Binding><Proteinases><Proteins><Proteolytic Enzymes><Receptor Protein><Regulation><Resistance><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS-Associated Coronavirus><SARS-CoV><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 entry inhibitor><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 inhibitor><SARS-CoV-2 pandemic><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Scientist><Serine Endopeptidase Inhibitors><Serine Protease Inhibitors><Serine Proteinase Antagonists><Serine Proteinase Inhibitors><Serpins><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 entry inhibitor><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 inhibitor><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome related corona virus 2><Strains Cell Lines><Structure><Surface><System><TMPRSS2><TMPRSS2 gene><Testing><Time><Tissues><Transgenic Organisms><Type A Influenza><Type II Pneumocyte><Vaccines><Viral><Viral Diseases><Virus><Virus Diseases><Work><Wuhan coronavirus><alveolar type II cell><angiotensin converting enzyme 2><angiotensin converting enzyme II><anti-viral agents><anti-viral drugs><anti-virals><block SARS-CoV-2><block SARS-CoV-2 entry><block severe acute respiratory syndrome coronavirus 2><block severe acute respiratory syndrome coronavirus 2 entry><block viral entry><bound protein><combat><corona virus disease><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus emergence><coronavirus disease><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 prevention><coronavirus disease 2019 public health crisis><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus emergence><cultured cell line><cytotoxicity><dosage><drug candidate><drug/agent><effective therapy><effective treatment><efficacy analysis><efficacy assessment><efficacy evaluation><efficacy examination><efficacy testing><emergent CoV><emergent corona virus><emergent coronavirus><emerging CoV><emerging corona virus><emerging coronavirus><evaluate efficacy><examine efficacy><feasibility testing><hCoV19><heavy metal Pb><heavy metal lead><human pluripotent stem cell><humanized mice><humanized mouse><iPS><iPSC><iPSCs><in vivo><induced pluripotent stem cell><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><infection rate><inhibit SARS-CoV-2><inhibit SARS-CoV-2 entry><inhibit severe acute respiratory syndrome coronavirus 2><inhibit severe acute respiratory syndrome coronavirus 2 entry><inhibit viral entry><inhibiting antibody><inhibitor><inhibitor/antagonist><insight><lung injury><mAbs><model of animal><model organism><mouse model><murine model><nCoV><nCoV2><neutralizing antibody><new CoV><new corona virus><new coronavirus><new drug treatments><new drugs><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><next generation therapeutics><novel><novel CoV><novel corona virus><novel coronavirus><novel drug treatments><novel drugs><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><pre-clinical><preclinical><prevent><prevent COVID-19><prevent COVID19><prevent coronavirus disease 2019><preventing><promoter><promotor><pulmonary><rate of infection><receptor><resistant><respiratory><respiratory virus><response><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><severe acute respiratory syndrome-CoV><stem cells><therapeutic candidate><therapeutically effective><three dimensional><transgenic><treat COVID-19><treat COVID19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><trend><viral entry blocker><viral entry inhibitor><viral infection><virus infection><virus-induced disease>